Atraverse Medical, a San Diego-based medical device company, has recently obtained U.S. Food and Drug Administration (FDA) clearance for its innovative Hotwire radiofrequency (RF) guidewire. This cutting-edge technology aims to enhance left-heart access for electrophysiologists during catheter-based therapy while ensuring precision and versatility.
The Hotwire RF guidewire boasts a distinctive feature known as “universal sheath compatibility,” allowing medical professionals to adhere to their preferred technology and workflow during RF procedures. The FDA clearance acts as a testament to Atraverse Medical’s commitment to medical innovation and improving the standard of care for transseptal access procedures such as endocardial ablation, left atrial appendage closure, and mitral valve repair.
Dr. Steven Mickelsen, a co-founder and the chief translational science officer of Atraverse, expressed his enthusiasm about the potential impact of the Hotwire. He highlighted its ability to empower physicians by facilitating safer and faster procedures, all while accommodating their preferred transseptal access workflow. Dr. Devi Nair, the director of cardiac electrophysiology and research at St. Bernard’s Medical Center, shared this excitement as an early user of the Hotwire. She praised the device’s efficacy in driving transformative changes in left-heart therapies.
With the FDA clearance for the Hotwire RF guidewire, Atraverse Medical aims to revolutionize left-heart procedures, providing improved outcomes and greater flexibility for physicians. This innovative technology marks a significant advancement in the field of cardiac electrophysiology and paves the way for enhanced patient care.